Genomic and proteomic analysis of multiple sclerosis: Opinion

Current Opinion in Immunology

Volumn 15, Issue 6, 2003, Pages 660-667

  Robinson, William H ^a,b   Utz, Paul J ^a   Steinman, Lawrence ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VA PALO ALTO HEALTH CARE SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL; CORTICOTROPIN; DNA VACCINE; LEPTIN; MELANOCORTIN 4 RECEPTOR; MESSENGER RNA; OSTEOPONTIN;

ALLERGIC ENCEPHALOMYELITIS; ALLERGY; AUTOIMMUNE DISEASE; B LYMPHOCYTE; DISEASE COURSE; DNA MICROARRAY; GENETIC TRANSCRIPTION; GENOME; HOMEOSTASIS; IMMUNOASSAY; MULTIPLE SCLEROSIS; MYELIN SHEATH; NONHUMAN; NUCLEOTIDE SEQUENCE; PROTEIN EXPRESSION; PROTEOMICS; RELAPSE; REMISSION; REVIEW; T LYMPHOCYTE;

EID: 0242575288     PISSN: 09527915     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.coi.2003.09.015     Document Type: Review

References (53)

1. Chabas D., Baranzini S.E., Mitchell D., Bernard C.C., Rittling S.R., Denhardt D.T., Sobel R.A., Lock C., Karpuj M., Pedotti R., et al. The influence of the proinflammatory cytokine, osteopontin, on autoimmune demyelinating disease. Science. 294:2001;1731-1735.
2. Lock C., Hermans G., Pedotti R., Brendolan A., Schadt E., Garren H., Langer-Gould A., Strober S., Cannella B., Allard J., et al. Gene-microarray analysis of multiple sclerosis lesions yields new targets validated in autoimmune encephalomyelitis. Nat. Med. 8:2002;500-508 This manuscript demonstrates the use of oligonucleotide array transcriptional profiling of human MS brain plaques to identify, and studies in EAE to validate, granulocyte colony-stimulating factor and IgFcRγ in order to elucidate new aspects of the pathophysiology of autoimmune demyelinating disease.
3. Steinman L., Zamvil S. Transcriptional analysis of targets in multiple sclerosis. Nat. Rev. Immunol. 3:2003;483-492.
4. Dyment D.A., Ebers G.C. An array of sunshine in multiple sclerosis. N. Engl. J. Med. 347:2002;1445-1447.
5. Whitney L.W., Becker K.G., Tresser N.J., Caballero-Ramos C.I., Munson P.J., Prabhu V.V., Trent J.M., McFarland H.F., Biddison W.E. Analysis of gene expression in mutiple sclerosis lesions using cDNA microarrays. Ann. Neurol. 46:1999;425-428.
6. Mycko M.P., Papoian R., Boschert U., Raine C.S., Selmaj K.W. cDNA microarray analysis in multiple sclerosis lesions: detection of genes associated with disease activity. Brain. 126:2003;1048-1057.
7. Ibrahim S.M., Mix E., Bottcher T., Koczan D., Gold R., Rolfs A., Thiesen H.J. Gene expression profiling of the nervous system in murine experimental autoimmune encephalomyelitis. Brain. 124:2001;1927-1938.
8. Nicot A., Ratnakar P.V., Ron Y., Chen C.C., Elkabes S. Regulation of gene expression in experimental autoimmune encephalomyelitis indicates early neuronal dysfunction. Brain. 126:2003;398-412.
9. Steinman L. Gene microarrays and experimental demyelinating disease: a tool to enhance serendipity. Brain. 124:2001;1897-1899.
10. Jansson M., Panoutsakopoulou V., Baker J., Klein L., Cantor H. Cutting edge: attenuated experimental autoimmune encephalomyelitis in eta-1/osteopontin-deficient mice. J. Immunol. 168:2002;2096-2099.
11. Steinman L., Youssef S., van Venrooij W.J., Chabas D., Baranzini S.E., Rittling S.R., Denhardt D.T., Sobel R.A., Lock C., Pedotti R., et al. Response to comment on 'The influence of the proinflammatory cytokine, osteopontin, on autoimmune demyelinating disease'. Science. 299:2003;1845.
12. Blom T, Franzen A, Heinegard D, Holmdahl R: Comment on 'The influence of the proinflammatory cytokine, osteopontin, on autoimmune demyelinating disease'. Science 2003, 299:1845; author reply 1845.
13. Caillier S, Barcellos L, Baranzini SE, Swerdlin A, Lincoln R, Steinman L, Oksenberg JR: Osteopontin polymorphisms and disease course in MS. Genes Immun 2003, in press.
14. Niino M., Kikuchi S., Fukazawa T., Yabe I., Tashiro K. Genetic polymorphisms of osteopontin in association with multiple sclerosis in Japanese patients. J. Neuroimmunol. 136:2003;125-129.
15. Vogt Mea: Elevated osteopontin levels are associated with disease activity in relapsing remitting MS patients. Ann Neurol 2003, in press.
16. Steinman L., Rosenbaum J.T., Sriram S., McDevitt H.O. In vivo effects of antibodies to immune response gene products: prevention of experimental allergic encephalitis. Proc. Natl. Acad. Sci. U.S.A. 78:1981;7111-7114.
17. Kwak B., Mulhaupt F., Myit S., Mach F. Statins as a newly recognized type of immunomodulator. Nat. Med. 6:2000;1399-1402.
18. Bottazzo G.F., Pujol-Borrell R., Hanafusa T., Feldmann M. Role of aberrant HLA-DR expression and antigen presentation in induction of endocrine autoimmunity. Lancet. 2:1983;1115-1119.
19. Waldor M.K., Sriram S., McDevitt H.O., Steinman L. In vivo therapy with monoclonal anti-I-A antibody suppresses immune responses to acetylcholine receptor. Proc. Natl. Acad. Sci. U.S.A. 80:1983;2713-2717.
20. Sriram S., Steinman L. Anti I-A antibody suppresses active encephalomyelitis: treatment model for diseases linked to IR genes. J. Exp. Med. 158:1983;1362-1367.
21. Vladutiu A.O., Steinman L. Inhibition of experimental autoimmune thyroiditis in mice by anti-I-A antibodies. Cell Immunol. 109:1987;169-180.
22. Youssef S., Stuve O., Patarroyo J.C., Ruiz P.J., Radosevich J.L., Hur E.M., Bravo M., Mitchell D.J., Sobel R.A., Steinman L., et al. The HMG-CoA reductase inhibitor, atorvastatin, promotes a Th2 bias and reverses paralysis in central nervous system autoimmune disease. Nature. 420:2002;78-84.
23. Neuhaus O., Strasser-Fuchs S., Fazekas F., Kieseier B.C., Niederwieser G., Hartung H.P., Archelos J.J. Statins as immunomodulators: comparison with interferon-beta 1b in MS. Neurology. 59:2002;990-997.
24. Zamvil S.S., Steinman L. Cholesterol-lowering statins possess anti-inflammatory activity that might be useful for treatment of MS. Neurology. 59:2002;970-971.
25. Sanna V., Di Giacomo A., La Cava A., Lechler R.I., Fontana S., Zappacosta S., Matarese G. Leptin surge precedes onset of autoimmune encephalomyelitis and correlates with development of pathogenic T cell responses. J. Clin. Invest. 111:2003;241-250.
26. Steinman L., Conlon P., Maki R., Foster A. The intricate interplay among body weight, stress, and the immune response to friend or foe. J. Clin. Invest. 111:2003;183-185.
27. Poliak S., Mor F., Conlon P., Wong T., Ling N., Rivier J., Vale W., Steinman L. Stress and autoimmunity: the neuropeptides corticotropin-releasing factor and urocortin suppress encephalomyelitis via effects on both the hypothalamic-pituitary-adrenal axis and the immune system. J. Immunol. 158:1997;5751-5756.
28. Ehrlich P. Die schutzstoffe des blutes. Dtsch Med. Wochenschr. 27:1901;913-916.
29. Pedotti R., Mitchell D., Wedemeyer J., Karpuj M., Chabas D., Hattab E.M., Tsai M., Galli S.J., Steinman L. An unexpected version of horror autotoxicus: anaphylactic shock to a self-peptide. Nat. Immunol. 2:2001;216-222.
30. Pedotti R., DeVoss J.J., Youssef S., Mitchell D., Wedemeyer J., Madanat R., Garren H., Fontoura P., Tsai M., Galli S.J., et al. Multiple elements of the allergic arm of the immune response modulate autoimmune demyelination. Proc. Natl. Acad. Sci. U.S.A. 100:2003;1867-1872.
31. Ma R.Z., Gao J., Meeker N.D., Fillmore P.D., Tung K.S., Watanabe T., Zachary J.F., Offner H., Blankenhorn E.P., Teuscher C. Identification of Bphs, an autoimmune disease locus, as histamine receptor H1. Science. 297:2002;620-623.
32. Steinman L. Multiple Sclerosis: a coordinated immunological attack against myelin in the central nervous system. Cell. 85:1996;299-302.
33. Warren K., Katz I., Steinman L. Fine specificity of the antibody response to myelin basic protein in the central nervous system in multiple sclerosis: the minimal B cell epitope and a model of its unique features. Proc. Natl. Acad. Sci. U.S.A. 92:1995;11061-11065.
34. Geysen H.M., Meloen R.H., Barteling S.J. Use of peptide synthesis to probe viral antigens for epitopes to a resolution of a single amino acid. Proc. Natl. Acad. Sci. U.S.A. 81:1984;3998-4002.
35. Ekins R.P. Multi-analyte immunoassay. J. Pharm. Biomed. Anal. 7:1989;155-168.
36. Fodor S.P., Read J.L., Pirrung M.C., Stryer L., Lu A.T., Solas D. Light-directed, spatially addressable parallel chemical synthesis. Science. 251:1991;767-773.
37. James J.A., Gross T., Scofield R.H., Harley J.B. Immunoglobulin epitope spreading and autoimmune disease after peptide immunization: Sm B/B′-derived PPPGMRPP and PPPGIRGP induce spliceosome autoimmunity. J. Exp. Med. 181:1995;453-461.
38. MacBeath G., Schreiber S. Printing proteins as microarrays for high-throughput function determination. Science. 289:2000;1760-1763.
39. Haab BB, Dunham MJ, Brown PO: Protein microarrays for highlyparallel detection and quantitation of specific proteins and antibodies in complex solutions. Genome Biol 2001, 2:research0004.1-0004.13 (ePub).
40. Joos T.O., Schrenk M., Hopfl P., Kroger K., Chowdhury U., Stoll D., Schorner D., Durr M., Herick K., Rupp S., et al. A microarray enzyme-linked immunosorbent assay for autoimmune diagnostics. Electrophoresis. 21:2000;2641-2650.
41. Robinson W.H., DiGennaro C., Hueber W., Haab B.B., Kamachi M., Dean E.J., Fournel S., Fong D., Genovese M.C., de Vegvar H.E., et al. Autoantigen microarrays for multiplex characterization of autoantibody responses. Nat. Med. 8:2002;295-301 This paper describes the development of protein arrays to detect autoantibodies in serum samples derived from patients with autoimmune disease.
42. Verge C.F., Gianani R., Kawasaki E., Yu L., Pietropaolo M., Jackson R.A., Chase H.P., Eisenbarth G.S. Prediction of type I diabetes in first-degree relatives using a combination of insulin, GAD, and ICA512bdc/IA-2 autoantibodies. Diabetes. 45:1996;926-933.
43. Schellekens G.A., de Jong B.A., van den Hoogen F.H., van de Putte L.B., van Venrooij W.J. Citrulline is an essential constituent of antigenic determinants recognized by rheumatoid arthritis-specific autoantibodies. J. Clin. Invest. 101:1998;273-281.
44. Schellekens G.A., Visser H., de Jong B.A., van den Hoogen F.H., Hazes J.M., Breedveld F.C., van Venrooij W.J. The diagnostic properties of rheumatoid arthritis antibodies recognizing a cyclic citrullinated peptide. Arthritis Rheum. 43:2000;155-163.
45. Robinson W.H., Fontoura P., Lee B.J., Neuman de Vegvar H.E., Tom J., Pedotti R., DiGennaro C., Mitchell D., Fong D., Ho P.P.K., et al. Reverse genomics: protein microarrays guide tolerizing DNA vaccine treatment of autoimmune encephalomyelitis. Nat. Biotechnol. 2:2003;1033-1039 This paper describes the application of protein arrays for prognostication, guiding the development and selection of antigen-specific therapy, and for monitoring responses to antigen-specific therapy in EAE.
46. Brocke S., Gijbels K., Allegretta M., Ferber I., Piercy C., Blankenstein T., Martin R., Utz U., Karin N., Mitchell D., et al. Treatment of experimental encephalomyelitis with a peptide analogue of myelin basic protein. Nature. 379:1996;343-346.
47. Critchfield J.M., Racke M.K., Zuniga-Pflucker J.C., Cannella B., Raine C.S., Goverman J., Lenardo M.J. T cell deletion in high antigen dose therapy of autoimmune encephalomyelitis. Science. 263:1994;1139-1143.
48. Garren H., Ruiz P.J., Watkins T.A., Fontoura P., Nguyen L.T., Estline E.R., Hirschberg D.L., Steinman L. Combination of gene delivery and DNA vaccination to protect from and reverse Th1 autoimmune disease via deviation to the Th2 pathway. Immunity. 15:2001;15-22.
49. Robinson W.H., Garren H., Utz P.J., Steinman L. Millennium award. proteomics for the development of DNA tolerizing vaccines to treat autoimmune disease. Clin. Immunol. 103:2002;7-12.
50. Walter G., Büssow K., Cahill D., Lueking A., Lehrach H. Protein arrays for gene expression and molecular interaction screening. Curr. Opin. Microbiol. 3:2000;298-302.
51. Lueking A., Horn M., Eickhoff H., Bussow K., Lehrach H., Walter G. Protein microarrays for gene expression and antibody screening. Anal. Biochem. 270:1999;103-111.
52. Casciola-Rosen L.A., Anhalt G.J., Rosen A. DNA-dependent protein kinase is one of a subset of autoantigens specifically cleaved early during apoptosis. J. Exp. Med. 182:1995;1625-1634.
53. Utz P.J., Gensler T.J., Anderson P. Death, autoantigen modifications, and tolerance. Arthritis Res. 2:2000;101-114.